SAN DIEGO (AP) _ Acadia Pharmaceuticals Inc. (ACAD) on Wednesday reported a loss of $84.7 million in its third quarter.

The San Diego-based company said it had a loss of 54 cents per share.

The results did not meet Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of 38 cents per share.

The drugmaker posted revenue of $120.6 million in the period, which topped Street forecasts. Seven analysts surveyed by Zacks expected $118.8 million.

Acadia shares have risen 15% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $49.13, an increase of 16% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ACAD at https://www.zacks.com/ap/ACAD

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News